A single Wegovy pen typically costs between $540 and $570 without insurance, which breaks down to approximately $400-$529 per month depending on your prescribed dose. For context, Health Canadas Drug Agency estimates annual Wegovy treatment at the list price costs approximately $5,066 per patient per year (roughly $420 per month) based on the recommended maintenance dose of 2.4 mg weekly. Current Promotional Pricing: Novo Nordisk offers a Wegovy Savings Program where self-pay patients can reduce costs to $149 per month for the 1.5 mg and 4 mg doses through April 15, 2026 (offer available for eligible patients only)

At baseline, most patients (97%) were treated with one or more glucose-lowering medications, including metformin (76%), insulin (51%), SGLT-2i (27%), sulfonylurea (29%), and DPP-4i (23%) with CV disease and risk factors managed with lipid-lowering medications (89%), platelet-aggregation inhibitors including aspirin (77%), angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (79%), and beta blockers (64%)
Contraindications and cautions include severe gastrointestinal disease, previous pancreatitis, and severe renal impairment (depending on the specific agent)
Always ask your health care professional for complete information about this product and your specific health needs
With a robust production capacity of 35 million units per year , our auto injector pen guarantees a stable global supply chain under BioauraHealth Global Standards